Robert A Lazarus

This inventor holds 36 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Cardiovascular Treatments. Top assignees: Genentech, Inc., Rutgers, The State University of New Jersey, Curis, Inc.. Active years: 1988-2021.

USPTO Granted Patents = 36 (Patent Applications = 8)

% Patents Active = 72.2

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 3.0

ph-index = 18

Forward Citations = 681(Granted Patents)

Location History:

San Mateo, CA (US) (1988)
Milbrae, CA (US) (1998 - 1999)
South San Francisco, CA (US) (1993 - 2017)
Millbrae, CA (US) (1991 - 2021)

Company Filing History:

Rutgers, The State University of New Jersey

where one patent can have more than one assignee

Years Active: 1988-2021

Loading Chart...

Areas of Expertise:

Cardiovascular Disease

BACE1 Inhibitors

Immunotherapy

Peptide Inhibitors

Nucleic Acid Molecules

Zymogen Activators

Enzymes

HGF Variants

Factor VIIa Inhibitors

Platelet Aggregation

Metabolic Pathway Engineering

Ascorbic Acid

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11034725 - Compositions and methods for treating cardiovascular disease (2021-06-15),

2. 10787484 - Compositions and methods for treating cardiovascular disease (2020-09-29),

3. 10562946 - Chagasin-based scaffold compositions, methods, and uses (2020-02-18),

4. 10005848 - Method of reducing blood glucose by administering RON agonists (2018-06-26),

5. 9879094 - Nucleic acid molecules encoding for BACE1 antibodies (2018-01-30),

6. 9624269 - Peptide inhibitors of BACE1 (2017-04-18),

7. 9453079 - Methods and compositions for neural disease immunotherapy (2016-09-27),

8. 9193766 - Peptide inhibitors of BACE1 (2015-11-24),

9. 8772457 - BACE1 antibodies (2014-07-08),

10. 8623997 - Variant Hhip1 protein and methods and uses thereof (2014-01-07),

11. 8623821 - Zymogen activators (2014-01-07),

12. 8110377 - HGF β chain variants (2012-02-07),

13. 7737115 - HGF beta chain variants (2010-06-15),

14. 7407785 - Human DNase I hyperactive variants (2008-08-05),

15. 7256027 - Enzymes for the production of 2-keto-L-gulonic acid (2007-08-14),

Title: Robert A Lazarus: Pioneering Innovations in Cardiovascular Disease Treatment

Introduction:

Robert A Lazarus is a prolific inventor hailing from Millbrae, CA, with an impressive tally of 36 patents to his name. His groundbreaking work in the field of cardiovascular disease treatment has revolutionized the industry and saved countless lives.

Latest Patents:

Among his latest patents are revolutionary "Compositions and methods for treating cardiovascular disease," which introduce PCSK9 inhibitors, innovative compositions containing these inhibitors, and cutting-edge techniques for identifying and utilizing them in medical treatments.

Career Highlights:

Lazarus has lent his exceptional talents to renowned companies such as Genentech, Inc., and Rutgers, the State University of New Jersey. His contributions to these esteemed organizations have been instrumental in driving forward the frontiers of medical science and healthcare technology.

Collaborations:

Throughout his illustrious career, Lazarus has collaborated closely with esteemed colleagues such as Mark S Dennis and Yingnan Zhang. Together, they have forged new paths in the development of life-saving therapies and revolutionary treatment methodologies.

Conclusion:

Robert A Lazarus stands as a shining example of innovation and dedication in the realm of medical research and patent development. His pioneering work in cardiovascular disease treatment continues to inspire and shape the future of healthcare, leaving an indelible mark on the industry and paving the way for groundbreaking advancements yet to come.